ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Condition(s):Uterine Cervical NeoplasmsLast Updated:July 27, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Uterine Cervical NeoplasmsLast Updated:July 27, 2023Active, not recruiting
Condition(s):Ovarian Cancer; Endometrial Cancer; Uterine Cervical CancerLast Updated:July 10, 2019Completed
Condition(s):Endometrial CancerLast Updated:September 21, 2023Completed
Condition(s):Ovarian CancerLast Updated:September 11, 2023Withdrawn
Condition(s):Cervical CancerLast Updated:July 25, 2023Completed
Condition(s):Ovarian CancerLast Updated:September 8, 2023Recruiting
Condition(s):Cervical CancerLast Updated:February 12, 2024Active, not recruiting
Condition(s):Cervical CancerLast Updated:November 1, 2019Withdrawn
Condition(s):Recurrent Ovarian CarcinomaLast Updated:January 2, 2024Active, not recruiting
Condition(s):Ovarian CancerLast Updated:August 2, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.